3-ethyl-3-methylindolin-2-one | 36797-37-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-ethyl-3-methylindolin-2-one
• 英文别名: 2H-Indol-2-one, 3-ethyl-1,3-dihydro-3-methyl-；3-ethyl-3-methyl-1H-indol-2-one
• CAS: 36797-37-2
• 化学式: C₁₁H₁₃NO
• 分子量: 175.23
• InChiKey: CTCPDMGHAXUIGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-ethyl-3-methylindolin-2-one 在 三氯化铝 、 乙酸酐 、 N,N-二甲基甲酰胺 作用下， 反应 1.0h， 生成 5-(3-Dimethylamino-2-methyl-propionyl)-3-ethyl-3-methyl-1,3-dihydro-indol-2-one
  参考文献：
  名称：

  Dihydropyridazinone cardiotonics. The discovery and inotropic activity of 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H-indol-2-one

  摘要：

  We discovered that 6 (N-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide) is a potent positive inotrope in dogs, and we have prepared several lactam analogues of this agent. These included 16 (1,3-dihydro-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H-indol-2-one), 32 (the analogous quinolin-2-one), and 37 (the analogous benzazepin-2-one). The inotropic ED50's of these compounds were 24, 3.3, and 5.2 micrograms/kg, respectively, after iv administration to pentobarbital-anesthetized dogs. Compound 20 (LY195115, 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H-i ndol-2- one), the geminal dimethyl analogue of 16, was 3.5-fold more potent than 16 when administered iv (ED50 = 6.8 micrograms/kg). However, the most profound effect of the geminal alkyl substitution was on oral activity. The approximate ED50's of 20 and 16 after oral administration to conscious dogs were 25 and 400 micrograms/kg, respectively. The increase in contractility produced by 25 micrograms/kg of 20 was maximally sustained in excess of 8 h. Thus, 20 is one of the most potent and long-acting oral inotropes described to date.

  DOI：

  10.1021/jm00160a006
• 作为产物：
  描述：

  3-甲基羟基吲哚 、 碘乙烷 在 正丁基锂 、 四甲基乙二胺 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 1.5h， 生成 3-ethyl-3-methylindolin-2-one
  参考文献：
  名称：

  PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS

  摘要：

  已发明的化合物为公式I的化合物以及其药用可接受的盐、酯和前药，这些化合物是DGAT2抑制剂。还提供了制备公式I化合物的方法，包含公式I化合物的药物组合物，以及使用这些化合物治疗肝脂肪变性、非酒精性脂肪肝炎（NASH）、纤维化、2型糖尿病、肥胖、高脂血症、高胆固醇血症、动脉粥样硬化、认知功能下降、痴呆、心肾疾病如慢性肾病和心力衰竭以及相关疾病和症状的方法，包括向需要的患者给予公式I的化合物。

  公开号：

  US20220112181A1

文献信息

• Regioselective Palladium(II)-Catalyzed Synthesis of Five- or Seven-Membered Ring Lactones and Five-, Six- or Seven-Membered Ring Lactams by Cyclocarbonylation Methodology
  作者：Bassam El Ali、Kazumi Okuro、Giuseppe Vasapollo、Howard Alper

  DOI：10.1021/ja953403l

  日期：1996.1.1

  affording five- or seven-membered ring lactones (bicyclic, tricyclic, and pentacyclic) as the principal products, often in excellent yields. Use of 2-aminostyrenes as reactants and catalytic quantities of palladium acetate and tricyclohexylphosphine, affords five-membered ring lactams in high yield and selectivity. Bicyclic and tricyclic heterocycles containing six-membered ring lactams can be synthesized

  2-烯丙基苯酚在催化量的阳离子钯 (II) 络合物 [(PCy3)2Pd(H)(H2O)]+BF4- 或乙酸钯和 1,4-双(二苯基膦) 存在下与一氧化碳和氢气反应丁烷，提供五元或七元环内酯（双环、三环和五环）作为主要产物，通常收率极好。使用 2-氨基苯乙烯作为反应物和催化量的乙酸钯和三环己基膦，以高产率和选择性提供五元环内酰胺。使用催化体系 Pd(OAc)2/PPh3，2-烯丙胺与 CO/H2 反应可以合成含有六元环内酰胺的双环和三环杂环，同时使用 1, 4-双（二苯基膦基）丁烷在后一过程中代替 PPh3 导致以良好的产率形成七元内酰胺苯并氮杂酮。区域化学控制取决于钯催化剂的性质、气体的相对压力和溶剂。
• Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
  申请人：Fensome Andrew

  公开号：US20060030615A1

  公开（公告）日：2006-02-09

  Pyrrole-oxindole derivatives useful as progesterone receptor antagonists are provided. Pharmaceutical compositions containing these derivatives are described, as is the use thereof in contraception and hormone-related conditions.

  提供了作为孕激素受体拮抗剂有用的吡咯-氧吲哚衍生物。描述了含有这些衍生物的药物组合物，以及在避孕和与激素相关疾病中使用它们的用途。
• Pharmaceutical compounds
  申请人：Eli Lilly and Company Limited

  公开号：US05773448A1

  公开（公告）日：1998-06-30

  A pharmaceutical compound of the formula ##STR1## and salts and esters thereof.

  一种药物化合物，其分子式为##STR1##，以及其盐和酯。
• 5HT1Dalpha and 5HT2A ligands
  申请人：LILLY INDUSTRIES LIMITED

  公开号：EP0780388A1

  公开（公告）日：1997-06-25

  A pharmaceutical compound of the formula in which R1 and R2 are each hydrogen, C1-4 alkyl, C1-4 alkoxy, HO-C1-4 alkyl, C1-4 alkoxy-C1-4 alkyl, C1-4 alkylthio, halo or phCR'R"- where Ph is optionally substituted phenyl and R' and R" are each hydrogen or C1-4 alkyl, or R1 and R2 together with the carbon atom to which they are attached form a C3-6 cycloalkyl group, R3, R4 and R5 are each hydrogen, halo, nitro, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkyl-CO-, C1-4 alkyl-S(O)m-where m is 0, 1 or 2, R'R"N-SO2-, -COOR', -CONR'R", -NR'R", -N(OR')COOR", -COR', -NHSO2R', where R' and R" are each hydrogen or C1-4 alkyl, R6 and R7 are each hydrogen or C1-4 alkyl, and n is 1 to 6, X is oxygen or sulphur, W is where p is 4 to 7, and q and r are each 1 to 3, Y is 〉CO or -CH(OH)-, and Z is optionally substituted phenyl or optionally substituted heteroaryl; and salts and esters thereof.

  一种药物化合物，其化学式为 其中 R1和R2各自为氢、C1-4烷基、C1-4烷氧基、HO-C1-4烷基、C1-4烷氧基-C1-4烷基、C1-4烷硫基、卤代或phCR'R"- 其中Ph为任选取代的苯基，R'和R "各自为氢或C1-4烷基，或R1和R2与其所连接的碳原子一起形成C3-6环烷基、 R3、R4 和 R5 各自为氢、卤代、硝基、C1-4 烷基、C1-4 烷氧基、C1-4 烷硫基、C1-4 烷基-CO-、C1-4 烷基-S(O)m-（其中 m 为 0、1 或 2）、R'R "N-SO2-、-COOR'、-CONR'R"、-NR'R"、-N(OR')COOR"、-COR'、-NHSO2R'，其中 R' 和 R "各自为氢或 C1-4 烷基、 R6 和 R7 分别为氢或 C1-4 烷基，n 为 1 至 6、 X 是氧或硫、 W 是 其中 p 为 4 至 7，q 和 r 各为 1 至 3、 Y 是 〉CO 或 -CH(OH)-、 和 Z 是任选取代的苯基或任选取代的杂芳基； 及其盐类和酯类。
• Indol-2-ones as serotonin modulators
  申请人：ELI LILLY AND COMPANY LIMITED

  公开号：EP0963983A1

  公开（公告）日：1999-12-15

  Pharmaceutical compounds of the formula: in which n is 1 to 6, m is 1 or 2 and p is 1 or 2, R1 and R2 are each hydrogen, C1-4 alkyl, C1-4 alkoxy, HO-C1-4 alkyl, C1-4 alkoxy-C1-4 alkyl, C1-4 alkylthio, halo, optionally substituted phenyl, optionally substituted phenyl-C1-4 alkyl, or R1 and R2 together with the carbon atom to which they are attached form a C3-6 cycloalkyl group, >C=O, C=NOR' where R' is hydrogen or C1-4 alkyl, R3, R4 and R5 are each hydrogen, halo, nitro, C1-4 alkyl, C1-4 alkoxy, C1-4 alkyl-CO-, where m is 0, 1 or 2, R'R"N-SO2-, -COOR', -CONR'R", -NR'R'', -N(OR')COOR'', -COR', -NHSO2R', where R' and R" are each hydrogen or C1-4 alkyl, R6 and R7 are each hydrogen or C1-4 alkyl, X is oxygen or sulphur, the dotted line represents an optional double bond, and the fluorine atom is attached at the 6- or 7-position; and salts thereof. Compounds (I) are active at the serotonin, 5-HT2A receptor.

  式的药物化合物： 其中 n 为 1 至 6，m 为 1 或 2，p 为 1 或 2、 R1和R2各自为氢、C1-4烷基、C1-4烷氧基、HO-C1-4烷基、C1-4烷氧基-C1-4烷基、C1-4烷硫基、卤代、任选取代的苯基、任选取代的苯基-C1-4烷基，或R1和R2与它们所连接的碳原子一起形成C3-6环烷基，>C=O，C=NOR'，其中R'为氢或C1-4烷基、 R3、R4 和 R5 各自为氢、卤素、硝基、C1-4 烷基、C1-4 烷氧基、C1-4 烷基-CO-（其中 m 为 0、1 或 2）、R'R "N-SO2-、-COOR'、-CONR'R"、-NR'R''、-N(OR')COOR''、-COR'、-NHSO2R'，其中 R' 和 R "各自为氢或 C1-4 烷基、 R6 和 R7 分别为氢或 C1-4 烷基、 X 是氧或硫、 虚线代表任选双键，氟原子连接在 6 位或 7 位；及其盐类。 化合物（I）对 5-羟色胺、5-HT2A 受体具有活性。